AAAAAA
Results:
1-7
|
Results: 7
Authors:
Olencki, T
Peereboom, D
Wood, L
Budd, GT
Novick, A
Finke, J
McLain, D
Elson, P
Bukowski, RM
Citation: T. Olencki et al., Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma, J CANC RES, 127(5), 2001, pp. 319-324
Authors:
Borden, EC
Lindner, D
Dreicer, R
Hussein, M
Peereboom, D
Citation: Ec. Borden et al., Second-generation interferons for cancer: clinical targets, SEM CANC B, 10(2), 2000, pp. 125-144
Authors:
Pelley, R
Ganapathi, R
Wood, L
Rybicki, L
McLain, D
Budd, GT
Peereboom, D
Olencki, T
Bukowski, RM
Citation: R. Pelley et al., A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer, CANC CHEMOT, 46(3), 2000, pp. 251-254
Authors:
Aldaabil, R
Peereboom, D
Citation: R. Aldaabil et D. Peereboom, Paraneoplastic syndromes in renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 135-145
Authors:
Hesketh, PJ
Crowley, JJ
Burris, HA
Williamson, SK
Balcerzak, SP
Peereboom, D
Goodwin, JW
Gross, HM
Moore, DF
Livingston, RB
Gandara, DR
Citation: Pj. Hesketh et al., Evaluation of docetaxel in previously untreated extensive-stage small celllung cancer: A Southwest Oncology Group phase II trial, CA J SCI AM, 5(4), 1999, pp. 237-241
Authors:
Bukowski, RM
Rayman, P
Molto, L
Tannenbaum, CS
Olencki, T
Peereboom, D
Tubbs, R
McLain, D
Budd, GT
Griffin, T
Novick, A
Hamilton, TA
Finke, J
Citation: Rm. Bukowski et al., Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma, CLIN CANC R, 5(10), 1999, pp. 2780-2789
Authors:
Rajagopalan, K
Peereboom, D
Budd, GT
Olencki, T
Murthy, S
Elson, P
McLain, D
Bukowski, R
Citation: K. Rajagopalan et al., Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer, INV NEW DR, 16(3), 1998, pp. 255-258
Risultati:
1-7
|